BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that members of its management and business development team will attend the 10th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, known as MSToronto2026, being held October 21–23, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. The joint ACTRIMS-ECTRIMS meeting is a premier international scientific forum uniting researchers, clinicians, and industry leaders focused on advances in multiple sclerosis (MS) and related neuroinflammatory disorders.

Company representatives will be available to discuss Tiziana’s clinical programs, including the INFORM-MS trial (NCT06292923) of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS), ongoing studies in Alzheimer’s disease, multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS), and opportunities for scientific collaboration and business development.

“We are pleased to attend and participate in MSToronto2026, one of the most important gatherings in the MS research community,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This meeting provides an excellent opportunity to engage with key opinion leaders, investigators, and potential partners as we advance intranasal foralumab, our novel fully human anti-CD3 monoclonal antibody designed to induce regulatory T cells and reduce microglial activation in neuroinflammatory and neurodegenerative diseases.”

About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923), as well as additional Phase 2 trials in AD and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and include statements regarding the closing of the Offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood

Strategic collaboration with the Global RDH12 Alliance supports the development of a potential treatment for this disease with high unmet need

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OPGx-RDH12, an investigational gene therapy for the treatment of RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited retinal disease that causes progressive vision loss and blindness beginning in early childhood.

The IND clearance enables Opus Genetics to advance OPGx-RDH12 into clinical development, marking an important achievement in the Company’s collaboration with the Global RDH12 Alliance, which brings together patient advocacy organizations RDH12 Fund for Sight in the United States and Eyes on the Future in the United Kingdom. The partnership was established in July 2025 with the goals of accelerating development of OPGx-RDH12 and bringing a potential treatment to patients living with this devastating condition.

“We are pleased to advance our third gene therapy pipeline program into clinical development and plan to initiate a Phase 1/2 trial this quarter,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “RDH12-LCA causes progressive vision loss beginning at a very young age, underscoring the urgency of developing treatments that may preserve vision before further deterioration occurs. Receiving IND clearance for OPGx-RDH12 represents an important step toward bringing a potentially transformative gene therapy to children and families affected by this devastating disease. We are grateful for the collaboration and commitment of our partners at the Global RDH12 Alliance, which has been instrumental in advancing this program into the clinic.”

“Bringing a treatment to the members of the RDH12-LCA community has been the stated goal of The RDH12 Fund for Sight since its founding more than a decade ago,” said Mathew Pletcher, Ph.D., Board member of the RDH12 Fund for Sight and father to a 20-year-old child living with RDH12-LCA. “From the foundational work, funded by patient dollars, in the lab of Dr. Jean Bennett through today’s announcement, the RDH12-LCA community has been collaborating with partners to ensure the delivery a potentially vision-saving therapy to the clinic.”

“This is what true co-development looks like,” said Silvia Cerolini, Chief Executive Officer of Eyes on the Future and mother of a child affected by RDH12-LCA. “Our RDH12 patient organizations and Opus have pooled resources, capabilities and risk to bring this rare gene therapy into the clinic, combining venture philanthropy, scientific innovation and a patient-driven sense of urgency. We have been working toward this moment for many years, and we are grateful to Opus for being a true partner. We believe this model can become a blueprint for bringing gene therapies to rare disease communities, and one that other patient organizations can follow.”

Under the strategic collaboration announced in July 2025, the Global RDH12 Alliance committed up to $1.6 million toward the development of OPGx-RDH12, with eligible development costs reimbursed as activities are completed subject to certain diligence obligations and milestones. The organizations are working together on the clinical and regulatory strategy for the program, integrating the perspectives and experiences of patients and families directly into its development.

About RDH12-LCA and OPGx-RDH12

RDH12-LCA is a rare form of childhood blindness affecting an estimated 30,900 people globally. Mutations in the RDH12 gene impair protein function in the retina, leading to early visual decline, often with structural retinal changes by age two, and rapid progression during adolescence. OPGx-RDH12 is an investigational adeno-associated virus (AAV)-based gene therapy designed to deliver a functional copy of the RDH12 gene directly to photoreceptor cells in the retina. Preclinical studies of OPGx-RDH12 in cell and mouse models have demonstrated restoration of RDH12 activity and functional improvements, supporting clinical evaluation of the therapeutic candidate.

About The RDH12 Fund for Sight

The RDH12 Fund for Sight is a registered 501(c)(3) not-for-profit organization based in the United States. The RDH12 Fund for Sight was founded for the express purpose of connecting and supporting families impacted by RDH12-LCA and to ensure that significant funds are devoted to the study and development of treatments for LCA caused by mutations in RDH12.

About Eyes on the Future

Eyes on the Future is a UK-based not-for-profit organization supporting research into rare diseases and eye diseases, with a specific focus on RDH12 inherited retinal dystrophies. Founded by Enrico and Silvia, whose 12-year-old child is affected by RDH12-LCA, Eyes on the Future is a registered company limited by guarantee in England and Wales (No. 13956181) and a registered charity (No. 1198330). More information is available at www.eyesonthefuture.org.uk.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, N.C. For more information, visit www.opusgtx.com.

Forward-Looking Statements

This press release contains certain statements that are not statements of historical fact and are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to the Company’s plans for the clinical development of OPGx-RDH12, including the anticipated timing of initiation, and the design, of the Phase 1/2 clinical trial of OPGx-RDH12; the therapeutic potential of OPGx-RDH12, including its potential to preserve vision or otherwise treat RDH12-LCA; the significance of preclinical data for OPGx-RDH12 and whether such data will be predictive of clinical results; the Company’s collaboration with the Global RDH12 Alliance and the potential of this partnership to accelerate development of OPGx-RDH12 and bring a potential treatment to patients living with this devastating condition; the Company’s ability to satisfy diligence obligations and meet development milestones under its agreement with the Global RDH12 Alliance and the potential of the collaboration model to be replicated to bring other gene therapies to rare disease communities; and the Company’s expectations regarding its business prospects and results of operations. There can be no assurance that the Company’s planned Phase 1/b clinical trial of OPGx-RDH12 will be initiated on the anticipated timeline or at all, or that OPGx-RDH12 will be shown to be safe or effective or receive regulatory approval.. The forward-looking statements contained herein are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the Company’s other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

Phase 1 Validates LT350’s Canopy and Modular Cartridge Architecture Across All Engineering Domains

Engagement Expands to Full Design/Engineering and Pilot Ready Deployment

Timeline Supports Breaking Ground on First LT350 Canopy at Texas Hospital in Q3 2027

BOULDER, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced the successful completion of Phase 1 of the LT350 design and engineering program with Fresh Consulting, concluding a comprehensive feasibility study of LT350’s distributed AI datacenter canopy platform. The study evaluated all major components of the LT350 architecture, including structural design, modular GPU cartridges, battery storage integration, microgrid controls, and an in-depth thermal analysis of high density GPU environments.

The Phase 1 results confirmed a feasible and scalable engineering solution, enabling LT350 to advance into Phase 2/3, which encompasses full design, detailed engineering, and pilot ready fabrication. LT350 executed the Phase 2/3 engagement last week, marking a major milestone in the Company’s path toward deploying its first operational canopy.

The completion of Phase 1 marks the next step in LT350’s engineering program with Fresh Consulting, first announced in June 2026. With the feasibility assessment of its patented canopy and modular cartridge architecture now complete, the program has advanced into detailed engineering and pilot preparation, bringing LT350 closer to its first planned deployment.

Phase 1 Feasibility Results

During Phase 1, Fresh Consulting conducted a multi-disciplinary engineering review of LT350’s patented canopy and cartridge architecture. The feasibility study included:

  • Structural engineering validation of the canopy platform and column footer design
  • Thermal modeling and analysis of GPU cartridge heat loads and zero-water liquid cooling performance
  • Electrical and microgrid feasibility including inverter systems, battery integration, and utility coordination
  • Cartridge modularity and manufacturability assessments
  • Deployment sequencing and site-readiness modeling

The study concluded that LT350’s distributed canopy architecture is technically feasible, scalable, and capable of supporting high-density inference workloads in a distributed, parking-lot-based datacenter environment.

Advancement to Phase 2/3 Engineering

With feasibility confirmation, LT350 and Fresh Consulting have entered Phase 2/3, which includes:

  • Final pilot stage canopy and cartridge design
  • Detailed engineering and pilot fabrication planning
  • Thermal system optimization
  • Electrical and microgrid integration engineering
  • Site-specific engineering for the first pilot canopy
  • Manufacturing preparation for modular cartridge production

This phase is designed to deliver a pilot ready engineering package, enabling LT350 to move directly into fabrication and site deployment.

Pilot Timeline: Breaking Ground in Q3 2027

The Phase 2/3 timeline supports breaking ground on LT350’s first operational canopy at a hospital in Texas in Q3 of next year, representing the Company’s first deployment of its distributed AI datacenter platform in a mission critical healthcare environment.

“We are extremely pleased with the results of the Phase 1 feasibility study,” said Jeff Thramann, CEO of Auddia and Founder of LT350. “Fresh Consulting validated the core engineering assumptions behind LT350 and delivered a clear path into full design and pilot deployment. Advancing into Phase 2/3 is a major milestone for LT350 and positions us to break ground on our first canopy next year.”

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

  • LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
  • Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
  • Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

  • Ad-free listening on any AM/FM radio station
  • Content skipping across any AM/FM station
  • One-touch skipping of entire podcast ad breaks
  • Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com

EVANSVILLE, Ind., Oct. 21, 2026 (GLOBE NEWSWIRE) —

Old National Bancorp (NASDAQ: ONB) reports 3Q26 net income applicable to common shares of $250.0 million, diluted EPS of $0.66; $249.7 million and $0.66 on an adjusted1 basis, respectively.
 

CEO COMMENTARY:

“With our strong 3rd quarter results, highlighted by record net income, a record efficiency ratio, and growth in both deposits and loans, Old National continues to demonstrate the strength and consistency of our operating model,” said Chairman and CEO Jim Ryan. “Our disciplined focus on fundamentals continues to drive profitable growth, positive operating leverage, and meaningful value creation for our shareholders. As we look ahead, we remain very well positioned to build on this momentum and capitalize on opportunities across our growing franchise.”
 

THIRD QUARTER HIGHLIGHTS2: 
Net Income
  • Record net income applicable to common shares of $250.0 million; adjusted net income applicable to common shares1 of $249.7 million
  • Earnings per diluted common share (“EPS”) of $0.66; record adjusted EPS1 of $0.66
Net Interest Income/NIM
  • Net interest income on a fully taxable equivalent basis1 of $592.0 million
  • Net interest margin on a fully taxable equivalent basis1 (“NIM”) of 3.52%, down 2 basis points (“bps”)
Operating Performance
  • Pre-provision net revenue1 (“PPNR”) of $365.0 million; adjusted PPNR1 of $364.8 million
  • Noninterest expense of $355.4 million; adjusted noninterest expense1 of $354.7 million
  • Record efficiency ratio1 of 46.1%; record adjusted efficiency ratio1 of 44.9%
Deposits and Funding
  • Period-end total deposits of $57.6 billion, up 10.6% annualized
  • Granular low-cost deposit franchise; total deposit costs of 179 bps, up 8 bps; interest-bearing deposit costs of 231 bps, up 8 bps
Loans and Credit Quality
  • End-of-period total loans3 of $51.2 billion, up $362.3 million or 2.9% annualized
  • Provision for credit losses4 (“provision”) of $33.6 million
  • Net charge-offs of $34.1 million, or 27 bps of average loans; 24 bps of average loans excluding purchased credit deteriorated (“PCD”) loans that had an allowance at acquisition
  • 30+ day delinquencies of 0.25% and nonaccrual loans of 0.92% of total loans
Return Profile & Capital
  • Return on average tangible common equity1 (“ROATCE”) of 19.6%; adjusted ROATCE1 of 19.6%
  • Preliminary regulatory Tier 1 common equity to risk-weighted assets of 11.11%, up 2 bps
  • Repurchased $100 million, or 3.9 million shares, of common stock during the quarter
Notable Items
  • $0.9 million of pre-tax pension gain5
  • $0.7 million of pre-tax merger-related charges
   

1 Non-GAAP financial measure that management believes is useful in evaluating the financial results of the Company – refer to the Non-GAAP reconciliations contained in this release     2 Comparisons are on a linked-quarter basis, unless otherwise noted     3 Includes loans held-for-sale     4 Includes the provision for unfunded commitments     5 Includes a gain associated with the settlement of the Bremer pension plan

RESULTS OF OPERATIONS2
Old National Bancorp reported record third quarter 2026 net income applicable to common shares of $250.0 million, or $0.66 per diluted common share.

Included in third quarter results was a $0.9 million pre-tax gain associated with the settlement of the Bremer pension plan and pre-tax charges of $0.7 million for merger-related expenses. Excluding these items and realized debt securities gains from the current quarter net of tax, adjusted net income1 was $249.7 million, or $0.66 per diluted common share.

DEPOSITS AND FUNDING
Increases in business and public funds.

  • Period-end total deposits were $57.6 billion, up 10.6% annualized.
  • On average, total deposits for the third quarter were $56.9 billion, an increase of $1.3 billion.
  • Granular low-cost deposit franchise; total deposit costs of 179 bps, up 8 bps.
  • A loan to deposit ratio of 89%, combined with existing funding sources, provides strong liquidity.

LOANS
Loan growth driven by high quality commercial loan production.

  • Period-end total loans3 were $51.2 billion, up $362.3 million or 2.9% annualized, including commercial and industrial growth of $148.0 million, as well as commercial real estate growth of $157.3 million.
  • Period-end commercial pipeline totaled $4.4 billion, down 20% from record levels at the end of the second quarter and up 6% from a year ago.
  • Average total loans in the third quarter were $51.1 billion, up 7.8% annualized.

CREDIT QUALITY
Credit quality remains stable.

  • Provision4 expense was $33.6 million compared to $36.2 million.
  • Net charge-offs were $34.1 million, or 27 bps of average loans, compared to 26 bps.
    • Excluding PCD loans that had an allowance for credit losses established at acquisition, net charge-offs to average loans were 24 bps compared to 22 bps.
  • 30+ day delinquencies as a percentage of loans were 0.25% compared to 0.29%.
  • Nonaccrual loans as a percentage of total loans were 0.92% compared to 0.91%.
  • The allowance for credit losses, including the allowance for credit losses on unfunded loan commitments, stood at $611.5 million, or 1.20% of total loans, compared to $612.0 million, or 1.21% of total loans.

NET INTEREST INCOME AND MARGIN
Earning asset growth and favorable rate/volume mix more than offset higher deposit costs.

  • Net interest income on a fully taxable equivalent basis1 increased to $592.0 million compared to $586.5 million, driven by high quality loan and deposit growth, partly offset by core deposit pricing and funding mix.
  • Net interest margin on a fully taxable equivalent basis1 decreased 2 bps to 3.52%.
  • Cost of total deposits was 1.79%, increasing 8 bps and the cost of total interest-bearing deposits increased 8 bps to 2.31%.

NONINTEREST INCOME
Bank and wealth fees remained resilient as other income normalized from elevated second quarter levels.

  • Total noninterest income was $128.4 million compared to $153.6 million, or $127.5 million compared to $140.4 million excluding pre-tax gains associated with the settlement of the Bremer pension plan.
  • Excluding the pension plan gains5 and realized debt securities gains, noninterest income was down 9.1% driven by approximately $10 million of elevated other income in the second quarter of 2026 due to market value adjustments, higher company-owned life insurance income and an asset recovery.

NONINTEREST EXPENSE
Disciplined expense management drives record adjusted efficiency ratio.

  • Noninterest expense was $355.4 million and included $0.7 million of merger-related charges.
  • Excluding merger related charges, adjusted noninterest expense1 decreased to $354.7 million, compared to $360.1 million.
  • The efficiency ratio1 was a record at 46.1%, while the adjusted efficiency ratio1 was a record at 44.9% compared to 47.0% and 45.2%, respectively.

INCOME TAXES

  • Income tax expense was $69.8 million, resulting in an effective tax rate of 21.6% compared to 21.8%. On an adjusted fully taxable equivalent (“FTE”) basis1, the effective tax rate was 23.4% compared to 23.0%.
  • Income tax expense included $9.5 million of tax credit benefit compared to $9.9 million.

CAPITAL
CET1 held at 11.11% while funding earning asset growth and returning $155 million to shareholders.

  • Preliminary total risk-based capital down 6 bps to 13.59% and preliminary regulatory Tier 1 capital up 1 bps to 11.54%, as growth in loans and share repurchases is partly offset by strong retained earnings.
  • Tangible common equity to tangible assets was 7.28% compared to 7.68%, driven by the $391 million impact of rates on other comprehensive income.
  • The Company repurchased $100 million of common stock and paid $55 million of quarterly common stock cash dividends during the quarter resulting in a combined payout ratio of 62%.

CONFERENCE CALL AND WEBCAST
Old National will host a conference call and live webcast at 9:00 a.m. Central Time on Wednesday, October 21, 2026, to review third quarter financial results. To listen to the live conference call, dial U.S./International (833) 461-5787, meeting ID 244 307 806. The live audio webcast link and corresponding presentation slides will be available on the Company’s Investor Relations website at oldnational.com and the webcast replay will be available approximately two hours after completion of the call until midnight ET on October 21, 2027.

ABOUT OLD NATIONAL
Old National Bancorp (NASDAQ: ONB) is the holding company of Old National Bank. As the sixth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $74 billion of assets and $41 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2026, Points of Light named Old National one of “The Civic 50” for the third consecutive year – an honor recognizing the 50 most community-minded companies in the United States – and also named Old National the Financials Sector Leader among nominated banks and financial services organizations.

USE OF NON-GAAP FINANCIAL MEASURES
The Company’s accounting and reporting policies conform to U.S. generally accepted accounting principles (“GAAP”) and general practices within the banking industry. As a supplement to GAAP, the Company provides non-GAAP performance results, which the Company believes are useful because they assist investors in assessing the Company’s operating performance. Where non-GAAP financial measures are used, the comparable GAAP financial measure, as well as the reconciliation to the comparable GAAP financial measure, can be found in the tables at the end of this release.

The Company presents EPS, the efficiency ratio, return on average common equity, return on average tangible common equity, pre-provision net revenue and net income applicable to common shares, all adjusted for certain notable items. These items include a pension plan gain/loss, merger-related charges associated with completed and pending acquisitions, realized debt securities gains/losses, distribution of excess pension assets expense, FDIC special assessment expense, and CECL Day 1 non-PCD provision expense. Management believes excluding these items from EPS, the efficiency ratio, return on average common equity, and return on average tangible common equity may be useful in assessing the Company’s underlying operational performance since these items do not pertain to its core business operations and their exclusion may facilitate better comparability between periods. Management believes that excluding merger-related charges from these metrics may be useful to the Company, as well as analysts and investors, since these expenses can vary significantly based on the size, type, and structure of each acquisition. Additionally, management believes excluding these items from these metrics may enhance comparability for peer comparison purposes.

Income tax expense, provision for credit losses, and the certain notable items listed above are excluded from the calculation of pre-provision net revenues, adjusted due to the fluctuation in income before income tax and the level of provision for credit losses required. Management believes adjusted pre-provision net revenues may be useful in assessing the Company’s underlying operating performance and their exclusion may facilitate better comparability between periods and for peer comparison purposes.

The Company presents adjusted noninterest expense, which excludes merger-related charges associated with completed and pending acquisitions, distribution of excess pension assets expense, and FDIC special assessment expense, as well as adjusted noninterest income, which excludes a pension plan gain/loss and realized debt securities gains/losses. Management believes that excluding these items from noninterest expense and noninterest income may be useful in assessing the Company’s underlying operational performance as these items either do not pertain to its core business operations or their exclusion may facilitate better comparability between periods and for peer comparison purposes.

The tax-equivalent adjustment to net interest income and net interest margin recognizes the income tax savings when comparing taxable and tax-exempt assets. Interest income and yields on tax-exempt securities and loans are presented using the current federal income tax rate of 21%. Management believes that it is standard practice in the banking industry to present net interest income and net interest margin on a fully tax-equivalent basis and that it may enhance comparability for peer comparison purposes.

In management’s view, tangible common equity measures are capital adequacy metrics that may be meaningful to the Company, as well as analysts and investors, in assessing the Company’s use of equity and in facilitating comparisons with peers. These non-GAAP measures are valuable indicators of a financial institution’s capital strength since they eliminate intangible assets from stockholders’ equity and retain the effect of accumulated other comprehensive loss in stockholders’ equity.

Although intended to enhance investors’ understanding of the Company’s business and performance, these non-GAAP financial measures should not be considered an alternative to GAAP. In addition, these non-GAAP financial measures may differ from those used by other financial institutions to assess their business and performance. See the following reconciliations in the “Non-GAAP Reconciliations” section for details on the calculation of these measures to the extent presented herein.

FORWARD-LOOKING STATEMENTS
This earnings release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”), Section 27A of the Securities Act of 1933 and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934 and Rule 3b-6 promulgated thereunder, notwithstanding that such statements are not specifically identified as such. In addition, certain statements may be contained in our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us that are not statements of historical fact and constitute forward‐looking statements within the meaning of the Act. These statements include, but are not limited to, descriptions of Old National’s financial condition, results of operations, asset and credit quality trends, profitability and business plans or opportunities. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “should,” “would,” and “will,” and other words of similar meaning. These forward-looking statements express management’s current expectations or forecasts of future events and, by their nature, are subject to risks and uncertainties. There are a number of factors that could cause actual results or outcomes to differ materially from those in such statements, including, but not limited to: competition; government legislation, regulations and policies, including trade and tariff policies; the ability of Old National to execute its business plan; unanticipated changes in our liquidity position, including but not limited to changes in our access to sources of liquidity and capital to address our liquidity needs; changes in economic conditions and economic and business uncertainty which could materially impact credit quality trends and the ability to generate loans and gather deposits; inflation and governmental responses to inflation, including increasing interest rates; market, economic, operational, liquidity, credit, and interest rate risks associated with our business; our ability to successfully manage our credit risk and the sufficiency of our allowance for credit losses; the potential impact of future business combinations on our performance and financial condition, including our ability to successfully integrate the businesses, the success of revenue-generating and cost reduction initiatives, and the diversion of management’s attention from ongoing business operations and opportunities; failure or circumvention of our internal controls; operational risks or risk management failures by us or critical third parties, including without limitation with respect to data processing, information systems, cybersecurity, technological changes, vendor issues, business interruption, and fraud risks; significant changes in accounting, tax or regulatory practices or requirements; new legal obligations or liabilities; disruptive technologies in payment systems and other services traditionally provided by banks; failure or disruption of our information systems; computer hacking and other cybersecurity threats; the effects of climate change on Old National and its customers, borrowers, or service providers; the impacts of pandemics, epidemics and other infectious disease outbreaks; other matters discussed in this earnings release; and other factors identified in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings with the SEC. These forward-looking statements are based on assumptions and estimates, which although believed to be reasonable, may turn out to be incorrect. Old National does not undertake an obligation to update these forward-looking statements to reflect events or conditions after the date of this earnings release. You are advised to consult further disclosures we may make on related subjects in our filings with the SEC.

CONTACTS:  
Media: Scott Reinhard Investors: Lynell Durchholz
(612) 716-0304 (812) 464-1366
Scott.Reinhard@oldnational.com Lynell.Durchholz@oldnational.com
   

               
Financial Highlights (unaudited)
($ and shares in thousands, except per share data)
                 
  Three Months Ended   Nine Months Ended
  September 30, June 30, March 31, December 31, September 30,   September 30, September 30,
    2026     2026     2026     2025     2025       2026     2025  
Income Statement                
Net interest income $ 584,287   $ 578,988   $ 572,573   $ 580,832   $ 574,609     $ 1,735,848   $ 1,477,042  
FTE adjustment1,3   7,667     7,510     7,849     8,013     7,975       23,026     20,398  
Net interest income – tax equivalent basis3   591,954     586,498     580,422     588,845     582,584       1,758,874     1,497,440  
Provision for credit losses   33,580     36,206     34,946     32,745     26,738       104,732     164,976  
Noninterest income   128,446     153,564     122,346     109,759     130,461       404,356     356,772  
Noninterest expense   355,380     372,161     364,704     386,320     445,734       1,092,245     1,098,971  
Net income applicable to common shareholders   249,960     249,381     229,638     212,589     178,533     $ 728,979     440,533  
Per Common Share Data                
Weighted average diluted shares   380,900     383,273     388,054     389,550     390,496       384,156     357,278  
EPS, diluted $ 0.66   $ 0.65   $ 0.59   $ 0.55   $ 0.46     $ 1.90   $ 1.23  
Cash dividends   0.145     0.145     0.145     0.140     0.140       0.44     0.42  
Dividend payout ratio2   22 %   22 %   25 %   25 %   30 %     23 %   34 %
Book value $ 21.26   $ 21.80   $ 21.40   $ 21.17   $ 20.64     $ 21.26   $ 20.64  
Stock price   24.64     25.90     22.10     22.31     21.95       24.64     21.95  
Tangible book value3   13.77     14.32     13.93     13.71     13.15       13.77     13.15  
Performance Ratios                
ROAA   1.37 %   1.38 %   1.29 %   1.21 %   1.03 %     1.35 %   0.95 %
ROAE   12.0 %   12.1 %   11.1 %   10.4 %   9.0 %     11.7 %   8.3 %
ROATCE3   19.6 %   19.8 %   18.4 %   17.8 %   15.9 %     19.3 %   14.3 %
NIM (FTE)3   3.52 %   3.54 %   3.55 %   3.65 %   3.64 %     3.53 %   3.50 %
Efficiency ratio3   46.1 %   47.0 %   48.3 %   51.6 %   58.8 %     47.1 %   56.4 %
NCOs to average loans   0.27 %   0.26 %   0.26 %   0.27 %   0.25 %     0.26 %   0.24 %
ACL on loans to EOP loans   1.13 %   1.14 %   1.15 %   1.17 %   1.19 %     1.13 %   1.19 %
ACL4to EOP loans   1.20 %   1.21 %   1.22 %   1.24 %   1.26 %     1.20 %   1.26 %
Nonaccrual loans to EOP loans   0.92 %   0.91 %   1.03 %   1.07 %   1.23 %     0.92 %   1.23 %
Balance Sheet (EOP)                
Total loans $ 51,148,063   $ 50,772,584   $ 49,731,844   $ 48,764,162   $ 47,967,915     $ 51,148,063   $ 47,967,915  
Total assets   74,423,980     74,189,417     73,002,651     72,151,967     71,210,162       74,423,980     71,210,162  
Total deposits   57,639,107     56,146,770     55,672,472     55,088,195     55,006,184       57,639,107     55,006,184  
Total borrowed funds   7,134,231     8,423,983     7,823,198     7,451,367     6,766,381       7,134,231     6,766,381  
Total shareholders’ equity   8,295,211     8,583,843     8,510,653     8,494,788     8,309,271       8,295,211     8,309,271  
Capital Ratios3                
Risk-based capital ratios (EOP):                
Tier 1 common equity   11.11 %   11.09 %   11.11 %   11.08 %   11.02 %     11.11 %   11.02 %
Tier 1 capital   11.54 %   11.53 %   11.56 %   11.53 %   11.49 %     11.54 %   11.49 %
Total capital   13.59 %   13.65 %   13.71 %   12.85 %   12.78 %     13.59 %   12.78 %
Leverage ratio (average assets)   8.98 %   8.95 %   8.93 %   8.90 %   8.72 %     8.98 %   8.72 %
Equity to assets (averages)   11.52 %   11.61 %   11.79 %   11.73 %   11.48 %     11.64 %   11.59 %
TCE to TA   7.28 %   7.68 %   7.67 %   7.72 %   7.53 %     7.28 %   7.53 %
Nonfinancial Data                
Full-time equivalent employees   4,894     4,914     4,948     4,971     5,243       4,894     5,243  
Banking centers   346     346     346     346     351       346     351  
1Calculated using the federal statutory tax rate in effect of 21% for all periods.          
2Cash dividends per common share divided by net income per common share (basic).          
3Represents a non-GAAP financial measure. Refer to the “Non-GAAP Measures” table for reconciliations to GAAP financial measures.      
4Includes the allowance for credit losses on loans and unfunded loan commitments.          
                 
September 30, 2026 capital ratios are preliminary.      
FTE – Fully taxable equivalent basis  ROAA – Return on average assets  ROAE – Return on average equity  ROATCE – Return on average tangible common equity  NCOs – Net Charge-offs  ACL – Allowance for Credit Losses  EOP – End of period actual balances  TCE – Tangible common equity  TA – Tangible assets      
       

                 
Income Statement (unaudited)
($ and shares in thousands, except per share data)
  Three Months Ended   Nine Months Ended
  September 30, June 30, March 31, December 31, September 30,   September 30, September 30,
    2026     2026     2026     2025     2025       2026     2025  
Interest income $ 916,830   $ 894,391   $ 877,391   $ 897,301   $ 917,192     $ 2,688,612   $ 2,372,552  
Less:  interest expense   332,543     315,403     304,818     316,469     342,583       952,764     895,510  
Net interest income   584,287     578,988     572,573     580,832     574,609       1,735,848     1,477,042  
Provision for credit losses   33,580     36,206     34,946     32,745     26,738       104,732     164,976  
Net interest income after provision for credit losses   550,707     542,782     537,627     548,087     547,871       1,631,116     1,312,066  
Wealth and investment services fees   42,244     42,098     39,715     39,012     39,684       124,057     105,149  
Service charges on deposit accounts   29,187     28,009     26,937     27,516     27,856       84,133     72,890  
Debit card and ATM fees   13,325     13,092     12,038     13,178     13,197       38,455     36,110  
Mortgage banking revenue   8,966     11,163     9,554     11,053     10,442       29,683     27,353  
Capital markets income   12,348     12,329     11,016     13,080     12,629       35,693     24,249  
Company-owned life insurance   7,326     8,531     7,561     7,099     7,565       23,418     19,571  
Other income   15,045     38,376     15,450     (1,252 )   19,081       68,871     71,560  
Debt securities gains (losses), net   5     (34 )   75     73     7       46     (110 )
Total noninterest income   128,446     153,564     122,346     109,759     130,461       404,356     356,772  
Salaries and employee benefits   180,018     184,765     184,073     187,251     211,345       548,856     561,762  
Occupancy   34,784     33,452     36,995     35,243     34,442       105,231     93,927  
Equipment   11,326     11,077     12,075     14,184     12,703       34,478     34,170  
Marketing   16,462     15,601     16,434     14,418     15,093       48,497     40,792  
Technology   27,529     29,630     29,025     30,882     36,122       86,184     89,594  
Communication   6,323     6,130     6,196     6,726     7,742       18,649     16,890  
Professional fees   12,260     10,735     12,356     18,454     13,598       35,351     43,448  
FDIC assessment   13,243     13,592     13,756     11,190     14,095       40,591     37,204  
Amortization of intangibles   23,331     23,992     25,623     26,016     26,184       72,946     52,644  
Amortization of tax credit investments   8,131     7,807     7,111     9,822     7,057       23,049     16,296  
Other expense   21,973     35,380     21,060     32,134     67,353       78,413     112,244  
Total noninterest expense   355,380     372,161     364,704     386,320     445,734       1,092,245     1,098,971  
Income before income taxes   323,773     324,185     295,269     271,526     232,598       943,227     569,867  
Income tax expense   69,779     70,771     61,597     54,903     50,031       202,147     117,233  
Net income $ 253,994   $ 253,414   $ 233,672   $ 216,623   $ 182,567     $ 741,080   $ 452,634  
Preferred dividends   (4,034 )   (4,033 )   (4,034 )   (4,034 )   (4,034 )     (12,101 )   (12,101 )
Net income applicable to common shares $ 249,960   $ 249,381   $ 229,638   $ 212,589   $ 178,533     $ 728,979   $ 440,533  
                 
EPS, diluted $ 0.66   $ 0.65   $ 0.59   $ 0.55   $ 0.46     $ 1.90   $ 1.23  
Weighted Average Common Shares Outstanding                
Basic   379,250     381,864     385,849     387,862     389,038       382,297     355,307  
Diluted   380,900     383,273     388,054     389,550     390,496       384,156     357,278  
(EOP)   378,639     382,537     386,315     389,662     390,768       378,639     390,768  
                 
                 

 
End of Period Balance Sheet (unaudited)
($ in thousands)
  September 30, June 30, March 31, December 31, September 30,
    2026     2026     2026     2025     2025  
Assets          
Cash and due from banks $ 507,214   $ 588,654   $ 537,322   $ 591,645   $ 491,910  
Money market and other interest-earning investments   1,171,814     1,179,526     1,216,826     1,234,532     1,190,707  
Investments:          
Treasury and government-sponsored agencies   2,312,713     2,358,509     2,371,903     2,427,371     2,402,375  
Mortgage-backed securities   10,275,345     10,460,468     10,295,623     10,078,358     10,117,015  
States and political subdivisions   1,393,309     1,442,703     1,454,444     1,570,888     1,579,802  
Other securities   814,729     821,719     814,990     825,761     849,911  
Total investments   14,796,096     15,083,399     14,936,960     14,902,378     14,949,103  
Loans held-for-sale, at fair value   30,456     43,608     56,128     52,911     80,341  
Loans:          
Commercial   16,260,724     16,112,685     15,617,656     14,983,861     14,506,375  
Commercial real estate   22,692,502     22,535,229     22,192,900     22,050,007     22,083,734  
Residential real estate   8,770,515     8,760,832     8,621,409     8,467,496     8,190,127  
Consumer   3,424,322     3,363,838     3,299,879     3,262,798     3,187,679  
Total loans   51,148,063     50,772,584     49,731,844     48,764,162     47,967,915  
Allowance for credit losses on loans   (579,658 )   (580,511 )   (574,358 )   (569,520 )   (572,178 )
Premises and equipment, net   674,192     682,065     690,400     690,824     691,950  
Goodwill and other intangible assets   2,839,096     2,862,427     2,886,419     2,907,986     2,926,960  
Company-owned life insurance   1,058,220     1,053,333     1,054,824     1,051,009     1,044,780  
Accrued interest receivable and other assets   2,778,487     2,504,332     2,466,286     2,526,040     2,438,674  
Total assets $ 74,423,980   $ 74,189,417   $ 73,002,651   $ 72,151,967   $ 71,210,162  
           
Liabilities and Equity          
Noninterest-bearing demand deposits $ 12,847,561   $ 12,665,278   $ 12,927,096   $ 13,247,483   $ 12,691,658  
Interest-bearing:          
Checking and NOW accounts   11,177,144     11,129,286     10,969,731     10,740,919     11,162,121  
Savings accounts   4,812,222     4,924,639     4,985,949     4,909,138     4,958,555  
Money market accounts   17,949,816     16,936,441     16,871,237     16,529,631     17,032,446  
Time deposits   10,852,364     10,491,126     9,918,459     9,661,024     9,161,404  
Total deposits   57,639,107     56,146,770     55,672,472     55,088,195     55,006,184  
           
Federal funds purchased and interbank borrowings   484     250,389     200,583     100,197     1  
Securities sold under agreements to repurchase   240,698     265,301     264,518     261,366     277,594  
Federal Home Loan Bank advances   5,484,611     6,520,296     6,026,801     6,237,375     5,663,361  
Other borrowings   1,408,438     1,387,997     1,331,296     852,429     825,425  
Total borrowed funds   7,134,231     8,423,983     7,823,198     7,451,367     6,766,381  
Accrued expenses and other liabilities   1,355,431     1,034,821     996,328     1,117,617     1,128,326  
Total liabilities   66,128,769     65,605,574     64,491,998     63,657,179     62,900,891  
Preferred stock, common stock, surplus, and retained earnings   9,244,597     9,141,984     9,053,907     8,973,459     8,833,662  
Accumulated other comprehensive income (loss), net of tax   (949,386 )   (558,141 )   (543,254 )   (478,671 )   (524,391 )
Total shareholders’ equity   8,295,211     8,583,843     8,510,653     8,494,788     8,309,271  
Total liabilities and shareholders’ equity $ 74,423,980   $ 74,189,417   $ 73,002,651   $ 72,151,967   $ 71,210,162  
 
 

                         
Average Balance Sheet and Interest Rates (unaudited)
($ in thousands)
                         
                         
    Three Months Ended   Three Months Ended   Three Months Ended
    September 30, 2026   June 30, 2026   September 30, 2025
    Average Income1/ Yield/   Average Income1/ Yield/   Average Income1/ Yield/
Earning Assets:   Balance Expense Rate   Balance Expense Rate   Balance Expense Rate
Money market and other interest-earning investments   $ 1,170,557   $ 10,979 3.72 %   $ 1,212,043   $ 11,121 3.68 %   $ 1,159,564   $ 12,207 4.18 %
Investments:                        
Treasury and government-sponsored agencies     2,358,480     19,370 3.29 %     2,349,871     18,993 3.23 %     2,391,564     20,721 3.47 %
Mortgage-backed securities     10,479,035     114,368 4.37 %     10,428,343     111,157 4.26 %     9,854,107     105,596 4.29 %
States and political subdivisions     1,417,175     11,844 3.34 %     1,450,389     12,017 3.31 %     1,577,384     13,109 3.32 %
Other securities     824,408     12,488 6.06 %     828,774     12,395 5.98 %     874,728     16,265 7.44 %
Total investments     15,079,098     158,070 4.19 %     15,057,377     154,562 4.11 %     14,697,783     155,691 4.24 %
Loans:2                        
Commercial     16,207,022     248,740 6.14 %     15,792,290     238,663 6.05 %     14,722,785     249,569 6.78 %
Commercial real estate     22,660,192     346,840 6.12 %     22,234,235     339,925 6.12 %     21,999,016     356,014 6.47 %
Residential real estate loans     8,800,325     104,378 4.74 %     8,722,341     103,162 4.73 %     8,287,155     95,129 4.59 %
Consumer     3,383,853     55,490 6.51 %     3,323,663     54,468 6.57 %     3,166,508     56,557 7.09 %
Total loans     51,051,392     755,448 5.92 %     50,072,529     736,218 5.88 %     48,175,464     757,269 6.28 %
                         
Total earning assets   $ 67,301,047   $ 924,497 5.49 %   $ 66,341,949   $ 901,901 5.44 %   $ 64,032,811   $ 925,167 5.78 %
                         
Less: Allowance for credit losses on loans     (592,670 )         (580,550 )         (566,102 )    
                         
Non-earning Assets:                        
Cash and due from banks   $ 526,400         $ 545,346         $ 492,415      
Other assets     7,040,733           6,991,436           7,177,663      
                         
Total assets   $ 74,275,510         $ 73,298,181         $ 71,136,787      
                         
Interest-Bearing Liabilities:                        
Checking and NOW accounts   $ 11,217,310   $ 52,484 1.86 %   $ 11,106,289   $ 47,349 1.71 %   $ 10,807,113   $ 52,301 1.92 %
Savings accounts     4,878,272     3,071 0.25 %     4,950,785     3,032 0.25 %     5,009,293     3,866 0.31 %
Money market accounts     17,085,773     104,643 2.43 %     16,485,000     99,903 2.43 %     17,007,426     125,717 2.93 %
Time deposits     10,831,986     96,449 3.53 %     10,145,661     87,220 3.45 %     9,337,597     90,717 3.85 %
Total interest-bearing deposits     44,013,341     256,647 2.31 %     42,687,735     237,504 2.23 %     42,161,429     272,601 2.57 %
                         
Federal funds purchased and interbank borrowings     9,668     90 3.69 %     42,228     391 3.71 %     157,192     1,816 4.58 %
Securities sold under agreements to repurchase     258,721     577 0.88 %     257,217     561 0.87 %     289,323     731 1.00 %
Federal Home Loan Bank advances     6,068,074     59,292 3.88 %     6,561,147     61,744 3.77 %     5,552,780     57,143 4.08 %
Other borrowings     1,449,183     15,937 4.36 %     1,360,976     15,203 4.48 %     871,996     10,292 4.68 %
Total borrowed funds     7,785,646     75,896 3.87 %     8,221,568     77,899 3.80 %     6,871,291     69,982 4.04 %
                         
Total interest-bearing liabilities   $ 51,798,987   $ 332,543 2.55 %   $ 50,909,303   $ 315,403 2.48 %   $ 49,032,720   $ 342,583 2.77 %
                         
Noninterest-Bearing Liabilities and Shareholders’ Equity:                      
Demand deposits   $ 12,837,453         $ 12,860,401         $ 12,731,654      
Other liabilities     1,083,626           1,020,272           1,203,838      
Shareholders’ equity     8,555,444           8,508,205           8,168,575      
                         
Total liabilities and shareholders’ equity   $ 74,275,510         $ 73,298,181         $ 71,136,787      
                         
Net interest rate spread       2.94 %       2.96 %       3.01 %
                         
Net interest margin (GAAP)       3.47 %       3.49 %       3.59 %
                         
Net interest margin (FTE)3       3.52 %       3.54 %       3.64 %
                         
FTE adjustment     $ 7,667       $ 7,510       $ 7,975  
                         
1Interest income is reflected on a FTE basis.  
2Includes loans held-for-sale.  
3Represents a non-GAAP financial measure. Refer to the “Non-GAAP Measures” table for reconciliations to GAAP financial measures.  
   

                 
Average Balance Sheet and Interest Rates (unaudited)
($ in thousands)
                 
                 
    Nine Months Ended   Nine Months Ended
    September 30, 2026   September 30, 2025
    Average Income1/ Yield/   Average Income1/ Yield/
Earning Assets:   Balance Expense Rate   Balance Expense Rate
Money market and other interest-earning investments   $ 1,199,047   $ 33,044 3.68 %   $ 1,126,460   $ 35,813 4.25 %
Investments:                
Treasury and government-sponsored agencies     2,375,485     57,484 3.23 %     2,369,307     61,560 3.46 %
Mortgage-backed securities     10,392,449     332,990 4.27 %     8,249,480     247,853 4.01 %
States and political subdivisions     1,463,885     36,402 3.32 %     1,594,912     39,753 3.32 %
Other securities     830,985     38,260 6.14 %     872,430     42,547 6.50 %
Total investments   $ 15,062,804   $ 465,136 4.12 %   $ 13,086,129   $ 391,713 3.99 %
Loans:2                
Commercial     15,771,532     720,843 6.09 %     12,803,059     634,610 6.61 %
Commercial real estate     22,319,323     1,022,713 6.11 %     19,432,867     918,371 6.30 %
Residential real estate loans     8,686,561     306,493 4.70 %     7,636,955     251,629 4.39 %
Consumer     3,326,422     163,409 6.57 %     3,030,102     160,814 7.10 %
Total loans     50,103,838     2,213,458 5.89 %     42,902,983     1,965,424 6.11 %
                 
Total earning assets   $ 66,365,689   $ 2,711,638 5.45 %   $ 57,115,572   $ 2,392,950 5.59 %
                 
Less: Allowance for credit losses on loans     (582,180 )         (457,192 )    
                 
Non-earning Assets:                
Cash and due from banks   $ 540,143         $ 430,891      
Other assets     7,025,532           6,331,698      
                 
Total assets   $ 73,349,184         $ 63,420,969      
                 
Interest-Bearing Liabilities:                
Checking and NOW accounts   $ 11,097,532   $ 146,128 1.76 %   $ 9,512,075   $ 123,627 1.74 %
Savings accounts     4,916,410     9,114 0.25 %     4,891,083     11,251 0.31 %
Money market accounts     16,706,478     304,502 2.44 %     14,697,398     328,533 2.99 %
Time deposits     10,246,260     267,738 3.49 %     8,215,063     239,773 3.90 %
Total interest-bearing deposits     42,966,680     727,482 2.26 %     37,315,619     703,184 2.52 %
                 
Federal funds purchased and interbank borrowings     18,532     504 3.64 %     131,341     4,394 4.47 %
Securities sold under agreements to repurchase     258,927     1,732 0.89 %     286,137     1,918 0.90 %
Federal Home Loan Bank advances     6,310,172     179,088 3.79 %     5,355,597     158,081 3.95 %
Other borrowings     1,328,586     43,958 4.42 %     792,708     27,933 4.71 %
Total borrowed funds     7,916,217     225,282 3.80 %     6,565,783     192,326 3.92 %
                 
Total interest-bearing liabilities     50,882,897     952,764 2.50 %     43,881,402     895,510 2.73 %
                 
Noninterest-Bearing Liabilities and Shareholders’ Equity:              
Demand deposits   $ 12,862,492         $ 11,145,709      
Other liabilities     1,067,798           1,041,715      
Shareholders’ equity     8,535,997           7,352,143      
                 
Total liabilities and shareholders’ equity   $ 73,349,184         $ 63,420,969      
                 
Net interest rate spread       2.95 %       2.86 %
                 
Net interest margin (GAAP)       3.49 %       3.45 %
                 
Net interest margin (FTE)3       3.53 %       3.50 %
                 
FTE adjustment     $ 23,026       $ 20,398  
                 
1Interest income is reflected on a FTE.
2Includes loans held-for-sale.                
3Represents a non-GAAP financial measure. Refer to the “Non-GAAP Measures” table for reconciliations to GAAP financial measures.    
     

                 
Asset Quality (EOP) (unaudited)
($ in thousands)
                 
  Three Months Ended   Nine Months Ended
  September 30, June 30, March 31, December 31, September 30,   September 30, September 30,
    2026     2026     2026     2025     2025       2026     2025  
Allowance for credit losses:                
Beginning allowance for credit losses on loans $ 580,511   $ 574,358   $ 569,520   $ 572,178   $ 565,109     $ 569,520   $ 392,522  
Allowance established for acquired PCD loans   —     —     —     —     13,104       —     103,546  
Provision for credit losses on loans   33,237     38,400     36,854     29,450     24,003       108,491     154,292  
Gross charge-offs   (48,275 )   (41,540 )   (37,307 )   (35,131 )   (35,402 )     (127,122 )   (89,896 )
Gross recoveries   14,185     9,293     5,291     3,023     5,364       28,769     11,714  
NCOs   (34,090 )   (32,247 )   (32,016 )   (32,108 )   (30,038 )     (98,353 )   (78,182 )
Ending allowance for credit losses on loans $ 579,658   $ 580,511   $ 574,358   $ 569,520   $ 572,178     $ 579,658   $ 572,178  
Beginning allowance for credit losses on unfunded commitments $ 31,531   $ 33,725   $ 35,633   $ 32,338   $ 29,603     $ 35,633   $ 21,654  
Provision (release) for credit losses on unfunded commitments   343     (2,194 )   (1,908 )   3,295     2,735       (3,759 )   10,684  
Ending allowance for credit losses on unfunded commitments $ 31,874   $ 31,531   $ 33,725   $ 35,633   $ 32,338     $ 31,874   $ 32,338  
Allowance for credit losses $ 611,532   $ 612,042   $ 608,083   $ 605,153   $ 604,516     $ 611,532   $ 604,516  
Provision for credit losses on loans $ 33,237   $ 38,400   $ 36,854   $ 29,450   $ 24,003     $ 108,491   $ 154,292  
Provision (release) for credit losses on unfunded commitments   343     (2,194 )   (1,908 )   3,295     2,735       (3,759 )   10,684  
Provision for credit losses $ 33,580   $ 36,206   $ 34,946   $ 32,745   $ 26,738     $ 104,732   $ 164,976  
NCOs / average loans1   0.27 %   0.26 %   0.26 %   0.27 %   0.25 %     0.26 %   0.24 %
Average loans1 $ 51,040,909   $ 50,062,552   $ 49,157,096   $ 48,199,086   $ 48,153,186     $ 50,093,753   $ 42,881,049  
EOP loans1   51,148,063     50,772,584     49,731,844     48,764,162     47,967,915       51,148,063     47,967,915  
ACL on loans / EOP loans1   1.13 %   1.14 %   1.15 %   1.17 %   1.19 %     1.13 %   1.19 %
ACL / EOP loans1   1.20 %   1.21 %   1.22 %   1.24 %   1.26 %     1.20 %   1.26 %
Underperforming Assets:                
Loans 90 days and over (still accruing) $ 4,079   $ 6,832   $ 4,407   $ 2,691   $ 1,525     $ 4,079   $ 1,525  
Nonaccrual loans   470,196     461,702     511,959     521,245     590,820       470,196     590,820  
Foreclosed assets   2,885     3,374     5,786     6,235     6,325       2,885     6,325  
Total underperforming assets $ 477,160   $ 471,908   $ 522,152   $ 530,171   $ 598,670     $ 477,160   $ 598,670  
Classified and Criticized Assets:                
Nonaccrual loans $ 470,196   $ 461,702   $ 511,959   $ 521,245   $ 590,820     $ 470,196   $ 590,820  
Substandard loans (still accruing)   1,737,688     1,918,721     1,881,374     1,759,221     1,881,294       1,737,688     1,881,294  
Loans 90 days and over (still accruing)   4,079     6,832     4,407     2,691     1,525       4,079     1,525  
Total classified loans – “problem loans”   2,211,963     2,387,255     2,397,740     2,283,157     2,473,639       2,211,963     2,473,639  
Other classified assets   6,861     7,960     20,620     20,616     35,373       6,861     35,373  
Special Mention   608,806     705,154     804,028     805,901     893,109       608,806     893,109  
Total classified and criticized assets $ 2,827,630   $ 3,100,369   $ 3,222,388   $ 3,109,674   $ 3,402,121     $ 2,827,630   $ 3,402,121  
Loans 30-89 days past due (still accruing) $ 126,202   $ 140,428   $ 114,038   $ 105,632   $ 83,030     $ 126,202   $ 83,030  
Nonaccrual loans / EOP loans1   0.92 %   0.91 %   1.03 %   1.07 %   1.23 %     0.92 %   1.23 %
ACL / nonaccrual loans   130 %   133 %   119 %   116 %   102 %     130 %   102 %
Under-performing assets/EOP loans1   0.93 %   0.93 %   1.05 %   1.09 %   1.25 %     0.93 %   1.25 %
Under-performing assets/EOP assets   0.64 %   0.64 %   0.72 %   0.73 %   0.84 %     0.64 %   0.84 %
30+ day delinquencies/EOP loans1   0.25 %   0.29 %   0.24 %   0.22 %   0.18 %     0.25 %   0.18 %
                 
1Excludes loans held-for-sale.            
                 

               

                 
Non-GAAP Measures (unaudited)
($ and shares in thousands, except per share data)
                 
  Three Months Ended   Nine Months Ended
  September 30, June 30, March 31, December 31, September 30,   September 30, September 30,
    2026     2026     2026     2025     2025       2026     2025  
Earnings Per Share:                
Net income applicable to common shares $ 249,960   $ 249,381   $ 229,638   $ 212,589   $ 178,533     $ 728,979   $ 440,533  
Adjustments:                
Pension plan loss (gain)   (893 )   (13,240 )   —     15,878     —       (14,133 )   (21,001 )
Tax effect1   160     2,890     —     (3,814 )   —       3,050     5,778  
Pension plan loss (gain), net   (733 )   (10,350 )   —     12,064     —       (11,083 )   (15,223 )
Merger-related charges   689     12,109     7,323     24,547     69,274       20,121     116,336  
Tax effect1   (199 )   (792 )   (1,810 )   (5,896 )   (16,494 )     (2,801 )   (28,921 )
Merger-related charges, net   490     11,317     5,513     18,651     52,780       17,320     87,415  
Debt securities (gains) losses   (5 )   34     (75 )   (73 )   (7 )     (46 )   110  
Tax effect1   1     (7 )   19     18     2       12     (24 )
Debt securities (gains) losses, net   (4 )   27     (56 )   (55 )   (5 )     (34 )   86  
Distribution of excess pension assets   —     —     3,394     —     —       3,394     —  
Tax effect1   —     —     (839 )   —     —       (839 )   —  
Distribution of excess pension assets, net   —     —     2,555     —     —       2,555     —  
FDIC special assessment   —     —     —     (2,994 )   —       —     —  
Tax effect1   —     —     —     719     —       —     —  
FDIC special assessment, net   —     —     —     (2,275 )   —       —     —  
CECL Day 1 non-PCD provision expense   —     —     —     —     —       —     75,604  
Tax effect1   —     —     —     —     —       —     (20,802 )
CECL Day 1 non-PCD provision expense, net   —     —     —     —     —       —     54,802  
Total adjustments, net   (247 )   994     8,012     28,385     52,775       8,758     127,080  
Net income applicable to common shares, adjusted $ 249,713   $ 250,375   $ 237,650   $ 240,974   $ 231,308     $ 737,737   $ 567,613  
Weighted average diluted common shares outstanding   380,900     383,273     388,054     389,550     390,496       384,156     357,278  
EPS, diluted $ 0.66   $ 0.65   $ 0.59   $ 0.55   $ 0.46     $ 1.90   $ 1.23  
Adjusted EPS, diluted $ 0.66   $ 0.65   $ 0.61   $ 0.62   $ 0.59     $ 1.92   $ 1.59  
NIM:                
Net interest income $ 584,287   $ 578,988   $ 572,573   $ 580,832   $ 574,609     $ 1,735,848   $ 1,477,042  
Add: FTE adjustment2   7,667     7,510     7,849     8,013     7,975       23,026     20,398  
Net interest income (FTE) $ 591,954   $ 586,498   $ 580,422   $ 588,845   $ 582,584     $ 1,758,874   $ 1,497,440  
Average earning assets $ 67,301,047   $ 66,341,949   $ 65,433,548   $ 64,456,815   $ 64,032,811     $ 66,365,689   $ 57,115,572  
NIM (GAAP)   3.47 %   3.49 %   3.50 %   3.60 %   3.59 %     3.49 %   3.45 %
NIM (FTE)   3.52 %   3.54 %   3.55 %   3.65 %   3.64 %     3.53 %   3.50 %
                 
Refer to last page of Non-GAAP reconciliations for footnotes.            
                 

                 
Non-GAAP Measures (unaudited)
($ in thousands)
                 
  Three Months Ended   Nine Months Ended
  September 30, June 30, March 31, December 31, September 30,   September 30, September 30,
    2026     2026     2026     2025     2025       2026     2025  
PPNR:                
Net interest income (FTE)2 $ 591,954   $ 586,498   $ 580,422   $ 588,845   $ 582,584     $ 1,758,874   $ 1,497,440  
Add: Noninterest income   128,446     153,564     122,346     109,759     130,461       404,356     356,772  
Total revenue (FTE)   720,400     740,062     702,768     698,604     713,045       2,163,230     1,854,212  
Less: Noninterest expense   (355,380 )   (372,161 )   (364,704 )   (386,320 )   (445,734 )     (1,092,245 )   (1,098,971 )
PPNR $ 365,020   $ 367,901   $ 338,064   $ 312,284   $ 267,311     $ 1,070,985   $ 755,241  
Adjustments:                
Pension plan loss (gain) $ (893 ) $ (13,240 ) $ —   $ 15,878   $ —     $ (14,133 ) $ (21,001 )
Debt securities (gains) losses   (5 )   34     (75 )   (73 )   (7 )     (46 )   110  
Noninterest income adjustments   (898 )   (13,206 )   (75 )   15,805     (7 )     (14,179 )   (20,891 )
Adjusted noninterest income   127,548     140,358     122,271     125,564     130,454       390,177     335,881  
Adjusted revenue $ 719,502   $ 726,856   $ 702,693   $ 714,409   $ 713,038     $ 2,149,051   $ 1,833,321  
Adjustments:                
Merger-related charges $ 689   $ 12,109   $ 7,323   $ 24,547   $ 69,274     $ 20,121   $ 116,336  
FDIC Special Assessment   —     —     —     (2,994 )   —       —     —  
Distribution of excess pension assets   —     —     3,394     —     —       3,394     —  
Noninterest expense adjustments   689     12,109     10,717     21,553     69,274       23,515     116,336  
Adjusted total noninterest expense   (354,691 )   (360,052 )   (353,987 )   (364,767 )   (376,460 )     (1,068,730 )   (982,635 )
Adjusted PPNR $ 364,811   $ 366,804   $ 348,706   $ 349,642   $ 336,578     $ 1,080,321   $ 850,686  
Efficiency Ratio:                
Noninterest expense $ 355,380   $ 372,161   $ 364,704   $ 386,320   $ 445,734     $ 1,092,245   $ 1,098,971  
Less: Amortization of intangibles   (23,331 )   (23,992 )   (25,623 )   (26,016 )   (26,184 )     (72,946 )   (52,644 )
Noninterest expense, excl. amortization of intangibles   332,049     348,169     339,081     360,304     419,550       1,019,299     1,046,327  
Less: Amortization of tax credit investments   (8,131 )   (7,807 )   (7,111 )   (9,822 )   (7,057 )     (23,049 )   (16,296 )
Less: Noninterest expense adjustments   (689 )   (12,109 )   (10,717 )   (21,553 )   (69,274 )     (23,515 )   (116,336 )
Adjusted noninterest expense, excluding amortization $ 323,229   $ 328,253   $ 321,253   $ 328,929   $ 343,219     $ 972,735   $ 913,695  
Total revenue (FTE)2 $ 720,400   $ 740,062   $ 702,768   $ 698,604   $ 713,045     $ 2,163,230   $ 1,854,212  
Less: Debt securities (gains) losses   (5 )   34     (75 )   (73 )   (7 )     (46 )   110  
Less: Pension plan loss (gain)   (893 )   (13,240 )   —     15,878     —       (14,133 )   (21,001 )
Total adjusted revenue $ 719,502   $ 726,856   $ 702,693   $ 714,409   $ 713,038     $ 2,149,051   $ 1,833,321  
Efficiency Ratio   46.1 %   47.0 %   48.3 %   51.6 %   58.8 %     47.1 %   56.4 %
Adjusted Efficiency Ratio   44.9 %   45.2 %   45.7 %   46.0 %   48.1 %     45.3 %   49.8 %
                 
Refer to last page of Non-GAAP reconciliations for footnotes.            
             

                 
Non-GAAP Measures (unaudited)
($ in thousands)
                 
  Three Months Ended   Nine Months Ended
  September 30, June 30, March 31, December 31, September 30,   September 30, September 30,
    2026     2026     2026     2025     2025       2026     2025  
ROAE and ROATCE:                
Net income applicable to common shares $ 249,960   $ 249,381   $ 229,638   $ 212,589   $ 178,533     $ 728,979   $ 440,533  
Amortization of intangibles   23,331     23,992     25,623     26,016     26,184       72,946     52,644  
Tax effect1   (5,833 )   (5,998 )   (6,406 )   (6,504 )   (6,546 )     (18,237 )   (13,161 )
Amortization of intangibles, net   17,498     17,994     19,217     19,512     19,638       54,709     39,483  
Net income applicable to common shares, excluding intangibles amortization   267,458     267,375     248,855     232,101     198,171       783,688     480,016  
Total adjustments, net (see pg.12)   (247 )   994     8,012     28,385     52,775       8,758     127,080  
Adjusted net income applicable to common shares, excluding intangibles amortization $ 267,211   $ 268,369   $ 256,867   $ 260,486   $ 250,946     $ 792,446   $ 607,096  
Average shareholders’ equity $ 8,555,444   $ 8,508,205   $ 8,544,220   $ 8,391,067   $ 8,168,575     $ 8,535,997   $ 7,352,143  
Less: Average preferred equity   (243,719 )   (243,719 )   (243,719 )   (243,719 )   (243,719 )     (243,719 )   (243,719 )
Average shareholders’ common equity $ 8,311,725   $ 8,264,486   $ 8,300,501   $ 8,147,348   $ 7,924,856     $ 8,292,278   $ 7,108,424  
Average goodwill and other intangible assets   (2,850,422 )   (2,873,898 )   (2,894,824 )   (2,919,924 )   (2,931,319 )     (2,872,886 )   (2,633,858 )
Average tangible shareholder’s common equity $ 5,461,303   $ 5,390,588   $ 5,405,677   $ 5,227,424   $ 4,993,537     $ 5,419,392   $ 4,474,566  
ROAE   12.0 %   12.1 %   11.1 %   10.4 %   9.0 %     11.7 %   8.3 %
ROAE, adjusted   12.0 %   12.1 %   11.5 %   11.8 %   11.7 %     11.9 %   10.6 %
ROATCE   19.6 %   19.8 %   18.4 %   17.8 %   15.9 %     19.3 %   14.3 %
ROATCE, adjusted   19.6 %   19.9 %   19.0 %   19.9 %   20.1 %     19.5 %   18.1 %
                 
Refer to last page of Non-GAAP reconciliations for footnotes.            
             

           
Non-GAAP Measures (unaudited)
($ in thousands)
           
  As of
  September 30, June 30, March 31, December 31, September 30,
    2026     2026     2026     2025     2025  
Tangible Common Equity:          
Shareholders’ equity $ 8,295,211   $ 8,583,843   $ 8,510,653   $ 8,494,788   $ 8,309,271  
Less: Preferred equity   (243,719 )   (243,719 )   (243,719 )   (243,719 )   (243,719 )
Shareholders’ common equity $ 8,051,492   $ 8,340,124   $ 8,266,934   $ 8,251,069   $ 8,065,552  
Less: Goodwill and other intangible assets   (2,839,096 )   (2,862,427 )   (2,886,419 )   (2,907,986 )   (2,926,960 )
Tangible shareholders’ common equity $ 5,212,396   $ 5,477,697   $ 5,380,515   $ 5,343,083   $ 5,138,592  
           
Total assets $ 74,423,980   $ 74,189,417   $ 73,002,651   $ 72,151,967   $ 71,210,162  
Less: Goodwill and other intangible assets   (2,839,096 )   (2,862,427 )   (2,886,419 )   (2,907,986 )   (2,926,960 )
Tangible assets $ 71,584,884   $ 71,326,990   $ 70,116,232   $ 69,243,981   $ 68,283,202  
           
Risk-weighted assets3 $ 56,350,807   $ 55,349,162   $ 54,283,745   $ 53,617,620   $ 52,515,468  
           
Tangible common equity to tangible assets   7.28 %   7.68 %   7.67 %   7.72 %   7.53 %
Tangible common equity to risk-weighted assets3   9.25 %   9.90 %   9.91 %   9.97 %   9.78 %
Tangible Common Book Value:          
Common shares outstanding   378,639     382,537     386,315     389,662     390,768  
Tangible common book value $ 13.77   $ 14.32   $ 13.93   $ 13.71   $ 13.15  
           
1Tax-effect calculations use management’s estimate of the full year FTE tax rates (federal + state).
2Calculated using the federal statutory tax rate in effect of 21% for all periods.
3September 30, 2026 figures are preliminary.
 

Targeting $30 Million in First-Year Supply Volume with Initial $2 million Purchase Order Already Secured

BREA, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Reborn Coffee, Inc. (Nasdaq: REBN) (the “Company” or “Reborn Coffee”), a leading innovator in specialty coffee, today announced that it has entered into a Master Product Supply Agreement (the “Agreement”) with Visvita Corporation (“Visvita”), a California-based beverage distribution company, under which Reborn Coffee will supply products to Visvita. Products covered by the Agreement are limited to aloe vera beverages and other beverage products the parties specify in approved purchase orders. The parties have agreed to work toward a minimum business volume of $30 million in products, raw materials and finished goods during the first contract year.

Reborn Coffee will supply products to Visvita on a non-exclusive basis, and individual purchase orders become binding only upon the Company’s written acceptance and confirmation. Upon signing the Agreement, the parties entered into an initial $2 million purchase order.

Reborn Coffee to be responsible for overseeing transport from South Korea to U.S warehouse

For the volume that Reborn Coffee supplies to Visvita, the Company will be responsible for logistics planning, including overseeing transport from the port in South Korea to the designated U.S warehouse. The Company plans to complete such shipments through Reborn Logistics, its ocean and inland freight subsidiary. Visvita remains solely responsible for FDA and other regulatory compliance in connection with manufacturing, U.S. importation and customs clearance.

“This agreement converts a framework into contracted volume and puts the freight economics in our hands,” said Jung Jae Lim, Chief Executive Officer of Reborn Coffee. “We set the supply price and the margin on every order, and plan to move the freight through Reborn Logistics instead of outside providers. That combination is what we believe turns a $30 million volume target into margin rather than revenue alone.”

“As Head of Global Sales Advisory for Reborn Coffee, I plan to mobilize our distribution network to establish Reborn’s signature matcha latte, milk coffee and other key products in the market,” said Michael Aminpour, President of Visvita Corporation and Head of Global Sales Advisory for Reborn Coffee. “We will dedicate our full efforts to the complete fulfillment of the $30 million annual minimum purchase target.”

About Reborn Coffee

Reborn Coffee, Inc. (NASDAQ: REBN) is a California-based specialty coffee retailer dedicated to delivering high-quality, artisanal coffee experiences. Committed to global expansion and innovation, Reborn is redefining the coffeehouse model through its premium offerings and technology-driven initiatives.

About Visvita

Visvita Corporation is a California-based beverage and distribution company with supplier relationships and retail distribution access across the Americas. Information regarding Visvita in this release has been provided by Visvita.

Forward-Looking Statements

This press release contains a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “plan,” “intend,” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future results and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond our control. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in more detail in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports filed with the SEC. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

Contacts

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
REBN@mzgroup.us
949-491-8235

Company Contact:
Reborn Coffee, Inc.
ir@reborncoffee.com

ST. LOUIS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.43 billion for the three months ended September 30, 2026, compared with $1.43 billion a year ago. Net income available to common shareholders was $224.8 million, or $1.40 per diluted common share, compared with $202.1 million, or $1.22 per diluted common share (1) for the third quarter of 2025. Non-GAAP net income available to common shareholders was $234.1 million, or $1.46 per diluted common share for the third quarter of 2026.

Ronald J. Kruszewski, Chairman and Chief Executive Officer, said “Stifel is on track for another record year, with year-to-date revenue of $4.3 billion up 9%, core earnings per share of $4.33 up 22%, and return on tangible common equity of 24.1%. The investments we’ve made in our business continued to drive operating efficiencies, as we delivered our highest ever third quarter earnings per share of $1.46, up 12% versus the prior year, on net revenue of $1.43 billion. I am optimistic about our outlook, as Stifel’s diversified business model, recurring revenue stream, and disciplined capital management position us to keep compounding value for shareholders.”

Highlights

  • The Company reported net revenues of $1.43 billion, the second best third quarter in its history, driven by higher asset management revenues and net interest income.
  • Non-GAAP net income available to common shareholders of $1.46 per diluted common share, the best third quarter in its history.
  • Asset management revenues increased 14% over the year-ago quarter.
  • Net interest income increased 9% over the year ago quarter.
  • Bank loans increased 21% over the year ago quarter.
  • Client assets of $576.5 billion, up 6% over the year-ago quarter.
  • Over the last twelve months, recruited trailing twelve-month production totaled approximately $19 million.
  • Non-GAAP pre-tax margin of 22.5%.
  • Annualized return on tangible common equity (ROTCE) (6) of 23.9%.
  • Tangible book value per common share (9) of $26.05, up 12% from prior year.
  • The Company repurchased $124.0 million, or 1.6 million shares, of its outstanding common stock during the third quarter at an average price of $76.95.
  • Announced strategic investment in Meow Technologies.
Financial Summary (Unaudited)
(000s) 3Q 2026 3Q 2025 9m 2026 9m 2025
GAAP Financial Highlights:      
Net revenues $1,426,211   $1,429,396   $4,355,176   $3,969,151  
Net income(2) $224,823   $202,051   $684,078   $391,457  
Diluted EPS(1) (2) $1.40   $1.22   $4.23   $2.37  
Comp. ratio   57.0%     58.8%     57.3%     59.1%  
Non-comp. ratio   21.3%     21.2%     21.2%     26.7%  
Pre-tax margin   21.7%     20.0%     21.5%     14.2%  
Non-GAAP Financial Highlights:      
Net revenues $1,429,077   $1,429,398   $4,323,903   $3,969,231  
Net income(2)(3) $234,096   $214,419   $700,872   $454,281  
Diluted EPS(1) (2) (3) $1.46   $1.30   $4.33   $2.76  
Comp. ratio(3)   56.6%     58.0%     57.0%     58.0%  
Non-comp. ratio(3)   20.9%     20.8%     20.9%     25.9%  
Pre-tax margin(4)   22.5%     21.2%     22.1%     16.1%  
ROCE(5)   17.4%     17.0%     17.5%     12.2%  
ROTCE(6)   23.9%     24.3%     24.1%     17.3%  
Global Wealth Management (assets and loans in millions)  
Net revenues $980,293   $907,440   $2,868,950   $2,603,630  
Pre-tax net income $374,408   $342,650   $1,066,970   $775,111  
Total client assets(7) $576,482   $544,010      
Fee-based client assets(7) $239,661   $219,178      
Bank loans(8) $26,065   $21,635      
Institutional Group        

Net revenues $430,281 $500,435 $1,406,233 $1,305,143
Equity $282,574 $296,677 $915,506 $753,037
Fixed Income $147,707 $203,758 $490,727 $552,106
Pre-tax net income $76,261 $89,291 $266,348 $177,762
                 

Global Wealth Management

Global Wealth Management reported record net revenues of $980.3 million for the three months ended September 30, 2026, compared with $907.4 million during the third quarter of 2025. Pre-tax net income was $374.4 million compared with $342.7 million in the third quarter of 2025.

Highlights

  • Client assets of $576.5 billion, up 6% over the year-ago quarter, which included $10.2 billion of client assets from the Stifel Independent Advisors business that was sold on February 2, 2026.
  • Fee-based client assets of $239.7 billion, up 9% over the year-ago quarter, which included $4.8 billion of client assets from the Stifel Independent Advisors business that was sold on February 2, 2026.
  • Over the last twelve months, recruited trailing twelve-month production totaled approximately $19 million.

Net revenues increased 8% from a year ago:

  • Transactional revenues decreased 3% over the year-ago quarter, reflecting a decrease in client activity.
  • Asset management revenues increased 14% over the year-ago quarter, reflecting higher asset values due to improved market conditions and net new asset growth.
  • Net interest income increased 11% over the year-ago quarter primarily driven by balance sheet growth, partially offset by lower interest rates.

Total Expenses:

  • Compensation expense as a percentage of net revenues increased modestly to 48.8% primarily driven by higher revenue-related compensation, partially offset by revenue growth.
  • Provision for credit losses decreased from a year ago primarily as a result of a modest improvement in macroeconomic conditions, partially offset by loan growth in the retained portfolio and specific reserves on individual credits.
  • Non-compensation operating expenses as a percentage of net revenues decreased to 13.0% primarily attributable to lower litigation-related expenses, a decrease in the provision for credit losses, and revenue growth over the year-ago quarter.
Summary Results of Operations
           
(000s)   3Q 2026   3Q 2025  
Net revenues $980,293 $907,440  
Transactional revenues   196,213   203,078  
Asset management   492,123   431,363  
Net interest income   284,583   257,327  
Investment banking   6,731   6,529  
Other income   643   9,143  

Total expenses $605,885   $564,790  
Compensation expense   478,877     441,626  
Provision for credit losses   7,926     8,316  
Non-comp. operating expenses   119,082     114,848  
Pre-tax net income $374,408   $342,650  
Compensation ratio   48.8%     48.7%  
Non-compensation ratio   13.0%     13.5%  
Pre-tax margin   38.2%     37.8%  
             

Institutional Group

Institutional Group reported net revenues of $430.3 million for the three months ended September 30, 2026, compared with $500.4 million during the third quarter of 2025. Pre-tax net income was $76.3 million compared with $89.3 million in the third quarter of 2025.

Highlights

Investment banking revenues decreased 6% from a year ago:

  • Advisory revenues decreased 4% from the year-ago quarter, driven by lower levels of completed advisory transactions.
  • Equity capital raising revenues decreased 13% from the year-ago quarter, driven by lower volumes and smaller deal sizes.
  • Fixed income capital raising revenues decreased 2% over the year-ago quarter primarily driven by lower bond issuances.

Fixed income transactional revenues decreased 34% from a year ago:

  • Fixed income transactional revenues were impacted by widening credit spreads, increased market volatility, and lower realized trading gains during the quarter.

Equity transactional revenues decreased 29% from a year ago:

  • Equity transactional revenues were impacted by lower realized trading gains, a decline in trading volumes over the year-ago quarter and the restructuring of our European Equities business, which resulted in a $7 million reduction in equity transactional revenues year over year.

Total Expenses:

  • Compensation expense as a percentage of net revenues decreased to 58.7% primarily attributable to lower revenue-related compensation due to a decline in revenues from the year ago quarter.
  • Non-compensation operating expenses as a percentage of net revenues increased to 23.6% primarily attributable to a decline in revenues from the year ago quarter.
Summary Results of Operations
 
(000s)   3Q 2026     3Q2025  
Net revenues $430,281   $500,435  
Investment banking   299,472     316,954  
Advisory   173,017     179,270  
Equity capital raising   68,556     78,765  
Fixed income capital raising   57,899     58,919  
Fixed income transactional   80,472     122,567  
Equity transactional   41,195     58,306  
Other   9,142     2,608  
Total expenses $354,020   $411,144  
Compensation expense   252,656     297,106  
Non-comp. operating expenses   101,364     114,038  
Pre-tax net income $76,261   $89,291  
Compensation ratio   58.7%     59.4%  
Non-compensation ratio   23.6%     22.8%  
Pre-tax margin   17.7%     17.8%  
             

Other Matters

Highlights

  • Total assets increased $3.6 billion, or 9%, from the year-ago quarter.
  • Over the last twelve months, the Company repurchased $564.4 million, or 7.3 million shares, of its outstanding common stock at an average price of $77.05.
  • Weighted average diluted shares outstanding decreased primarily due to share repurchases.
  • The Board of Directors declared a $0.34 quarterly dividend per share, payable on September 15, 2026, to common shareholders of record on September 1, 2026.
  • The Board of Directors declared a quarterly dividend on the outstanding shares of the Company’s preferred stock, payable on September 15, 2026, to shareholders of record on September 1, 2026.
  3Q 2026
  3Q 2025
 
Common stock repurchases(1)    
Repurchases (000s) $124,005   $33,086  
Number of shares (000s)   1,612     438  
Average price $76.95   $75.57  
Period end shares (000s)   150,061     152,922  
Weighted average diluted shares outstanding (000s)   160,145     165,087  
Effective tax rate   24.4%     26.1%  
Stifel Financial Corp.(10)    
Tier 1 common capital ratio `14.5%   14.8%  
Tier 1 risk-based capital ratio   17.0%     17.6%  
Tier 1 leverage capital ratio   10.8%     11.1%  
Tier 1 capital (MM) $4,665   $4,267  
Risk weighted assets (MM) $27,450   $24,235  
Average assets (MM) $43,060   $38,332  
Quarter end assets (MM) $45,282   $41,687  
Agency Rating Outlook
Fitch Ratings BBB+ Stable
S&P Global Ratings BBB Stable
     

Conference Call Information

Stifel Financial Corp. will host its third quarter 2026 financial results conference call on Wednesday, October 21, 2026, at 9:30 a.m. Eastern Time. The conference call may include forward-looking statements.

All interested parties are invited to listen to Stifel’s Chairman and CEO, Ronald J. Kruszewski, by dialing (800) 330-6710 and referencing conference ID 9806728. A live audio webcast of the call, as well as a presentation highlighting the Company’s results, will be available through the Company’s web site, www.stifel.com. For those who cannot listen to the live broadcast, a replay of the broadcast will be available through the above-referenced web site beginning approximately one hour following the completion of the call.

Company Information

Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with retail and institutional clients aiming to transform opportunities into achievement. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit www.stifel.com/investor-relations/press-releases.

A financial summary follows. Financial, statistical and business-related information, as well as information regarding business and segment trends, is included in the financial supplement. Both the earnings release and the financial supplement are available online in the Investor Relations section at www.stifel.com/investor-relations.

The information provided herein and in the financial supplement, including information provided on the Company’s earnings conference calls, may include certain non-GAAP financial measures. The definition of such measures or reconciliation of such measures to the comparable U.S. GAAP figures are included in this earnings release and the financial supplement, both of which are available online in the Investor Relations section at www.stifel.com/investor-relations.

Cautionary Note Regarding Forward-Looking Statements

This earnings release contains certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements in this earnings release not dealing with historical results are forward-looking and are based on various assumptions. The forward-looking statements in this earnings release are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, among other things, the following possibilities: the ability to successfully integrate acquired companies or the branch offices and financial advisors; a material adverse change in financial condition; the risk of borrower, depositor, and other customer attrition; a change in general business and economic conditions; changes in the interest rate environment, deposit flows, loan demand, real estate values, and competition; changes in accounting principles, policies, or guidelines; changes in legislation and regulation; other economic, competitive, governmental, regulatory, geopolitical, and technological factors affecting the companies’ operations, pricing, and services; and other risk factors referred to from time to time in filings made by Stifel Financial Corp. with the Securities and Exchange Commission. For information about the risks and important factors that could affect the Company’s future results, financial condition and liquidity, see “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Forward-looking statements speak only as to the date they are made. The Company disclaims any intent or obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Summary Results of Operations (Unaudited)
       
  Three Months Ended   Nine Months Ended
(000s, except per share amounts) 9/30/2026 9/30/2025 % Change 6/30/2026 % Change 9/30/2026 9/30/2025 % Change
Revenues:                
Commissions $200,756 $206,075 (2.6)   $221,462 (9.3)   $630,052 $600,414 4.9  
Principal transactions   117,124   177,876 (34.2)     140,091 (16.4)     407,436   492,139 (17.2)  
Investment banking   306,203   323,483 (5.3)     331,954 (7.8)     979,569   794,885 23.2  
Asset management   492,163   431,399 14.1     456,630 7.8     1,408,250   1,244,548 13.2  
Other income   8,299   14,228 (41.7)     12,549 (33.9)     76,527   28,499 168.5  
Operating revenues   1,124,545   1,153,061 (2.5)     1,162,686 (3.3)     3,501,834   3,160,485 10.8  
Interest revenue   510,624   481,504 6.0     476,093 7.3     1,437,766   1,434,192 0.2  
Total revenues   1,635,169   1,634,565 0.0     1,638,779 (0.2)     4,939,600   4,594,677 7.5  
Interest expense   208,958   205,169 1.8     187,975 11.2     584,424   625,526 (6.6)  
Net revenues   1,426,211   1,429,396 (0.2)     1,450,804 (1.7)     4,355,176   3,969,151 9.7  
Non-interest expenses:                
Compensation and benefits   813,494   839,820 (3.1)     833,018 (2.3)     2,494,846   2,346,976 6.3  
Non-compensation operating expenses   303,092   303,530 (0.1)     318,348 (4.8)     925,195   1,058,945 (12.6)  
Total non-interest expenses   1,116,586   1,143,350 (2.3)     1,151,366 (3.0)     3,420,041   3,405,921 0.4  
Income before income taxes   309,625   286,046 8.2     299,438 3.4     935,135   563,230 66.0  
Provision for income taxes   75,482   74,675 1.1     72,961 3.5     223,096   143,812 55.1  
Net income   234,143   211,371 10.8     226,477 3.4     712,039   419,418 69.8  
Preferred dividends   9,320   9,320 0.0     9,321 (0.0)     27,961   27,961 0.0  
Net income available to common shareholders $224,823 $202,051 11.3   $217,156 3.5   $684,078 $391,457 74.8  
Earnings per common share:(1)              
Basic $1.48 $1.31 13.0   $1.41 5.0   $4.45 $2.52 76.6  
Diluted $1.40 $1.22 14.8   $1.34 4.5   $4.23 $2.37 78.5  
Cash dividends declared per common share(1) $0.34 $0.31 9.7   $0.34 0.0   $1.02 $0.93 9.7  
Weighted average number of common shares outstanding:(1)          
Basic   151,956   154,679 (1.8)     154,234 (1.5)     153,889   155,603 (1.1)  
Diluted   160,145   165,087 (3.0)     161,631 (0.9)     161,744   164,877 (1.9)  
                                 

Non-GAAP Financial Measures (11)
     
  Three Months Ended Nine Months Ended
(000s, except per share amounts) 9/30/2026 9/30/2025 9/30/2026 9/30/2025
GAAP net income   234,143   $ 211,371     712,039   $ 419,418  
Preferred dividend   9,320     9,320     27,961     27,961  
Net income available to common shareholders   224,823     202,051     684,078     391,457  
         
Non-GAAP adjustments:        
Net revenue adjustments (12) (13)   2,866     2     (31,273 )   80  
Merger-related (14)   8,219     12,676     50,090     45,635  
Restructuring and severance (15)   1,174     4,065     3,504     31,106  
Provision for income taxes (16)   (2,986 )   (4,375 )   (5,527 )   (13,997 )
Total non-GAAP adjustments   9,273     12,368     16,794     62,824  
Non-GAAP net income available to common shareholders $ 234,096   $ 214,419   $ 700,872   $ 454,281  
         
Weighted average diluted shares outstanding (1)   160,145     165,087     161,744     164,877  
         
GAAP earnings per diluted common share (1) $ 1.46   $ 1.28   $ 4.41   $ 2.53  
Non-GAAP adjustments (1)   0.06     0.08     0.10     0.39  
Non-GAAP earnings per diluted common share (1) $ 1.52   $ 1.36   $ 4.51   $ 2.92  
         
GAAP earnings per diluted common share available to common shareholders (1) $ 1.40   $ 1.22   $ 4.23   $ 2.37  
Non-GAAP adjustments (1)   0.06     0.08     0.10     0.39  
Non-GAAP earnings per diluted common share available to common shareholders (1) $ 1.46   $ 1.30   $ 4.33   $ 2.76  
                         

GAAP to Non-GAAP Reconciliation (11)
     
  Three Months Ended Nine Months Ended
(000s) 9/30/2026 9/30/2025 9/30/2026 9/30/2025
GAAP net revenues $1,426,211   $1,429,396   $4,355,176   $3,969,151  
Non-GAAP adjustments:        
Gain on sale of business (12)   2,866     —     (44,418 )   —  
Litigation-related and other (13)   —     2     13,145     80  
Total non-GAAP adjustments   2,866     2     (31,273 )   80  
Non-GAAP net revenues $1,429,077   $1,429,398   $4,323,903   $3,969,231  
         
GAAP compensation and benefits $813,494   $839,820   $2,494,846   $2,346,976  
As a percentage of net revenues   57.0%     58.8%     57.3%     59.1%  
Non-GAAP adjustments:        
Merger-related (14)   (3,463 )   (6,704 )   (25,226 )   (13,706 )
Restructuring and severance (15)   (1,174 )   (4,065 )   (3,504 )   (31,106 )
Total non-GAAP adjustments   (4,637 )   (10,769 )   (28,730 )   (44,812 )
 Non-GAAP compensation and benefits $808,857   $829,051   $2,466,116   $2,302,164  
As a percentage of non-GAAP net revenues   56.6%     58.0%     57.0%     58.0%  
         
GAAP non-compensation expenses $303,092   $303,530   $925,195   $1,058,945  
As a percentage of net revenues   21.3%     21.2%     21.2%     26.7%  
Non-GAAP adjustments:        
Merger-related (14)   (4,756 )   (5,972 )   (24,864 )   (31,929 )
 Non-GAAP non-compensation expenses $298,336   $297,558   $900,331   $1,027,016  
As a percentage of non-GAAP net revenues   20.9%     20.8%     20.9%     25.9%  
Total adjustments before income taxes $12,259   $16,743   $22,321   $76,821  
                         

Footnotes
   
(1) All share and per share information has been retroactively adjusted to reflect the February 2026 three-for-two stock split.
(2) Represents available to common shareholders.
(3) Reconciliations of the Company’s GAAP results to these non-GAAP measures are discussed within and under “Non-GAAP Financial Measures” and “GAAP to Non-GAAP Reconciliation.”
(4) Non-GAAP pre-tax margin is calculated by adding total merger-related expenses (non-GAAP adjustments) and dividing it by non-GAAP net revenues. See “Non-GAAP Financial Measures” and “GAAP to Non-GAAP Reconciliation.”
(5) Return on average common equity (“ROCE”), a non-GAAP financial measure, is calculated by dividing full year or annualized net income applicable to common shareholders by average common shareholders’ equity.
(6) Return on average tangible common equity (“ROTCE”), a non-GAAP financial measure, is calculated by dividing full year or annualized net income applicable to common shareholders by average tangible common equity. Tangible common equity, also a non-GAAP financial measure, equals total common shareholders’ equity less goodwill and identifiable intangible assets and the deferred taxes on goodwill and intangible assets. Average deferred taxes on goodwill and intangible assets were $95.0 million and $87.2 million as of September 30, 2026, and 2025, respectively.
(7) Total client assets and fee-based client assets as of September 30, 2025, include $10.2 billion and $4.8 billion, respectively, of client assets from the Stifel Independent Advisors business that was sold on February 2, 2026.
(8) Includes loans held for sale.
(9) Tangible book value per common share, a non-GAAP financial measure, represents shareholders’ equity (excluding preferred stock) divided by period end common shares outstanding. Tangible common shareholders’ equity equals total common shareholders’ equity less goodwill and identifiable intangible assets and the deferred taxes on goodwill and intangible assets.
(10) Capital ratios are estimates at the time of the Company’s earnings release, October 21, 2026.
(11) The Company prepares its Consolidated Financial Statements using accounting principles generally accepted in the United States (U.S. GAAP). The Company may disclose certain “non-GAAP financial measures” during its earnings releases, earnings conference calls, financial presentations and otherwise. The Securities and Exchange Commission defines a “non-GAAP financial measure” as a numerical measure of historical or future financial performance, financial position, or cash flows that is subject to adjustments that effectively exclude, or include, amounts from the most directly comparable measure calculated and presented in accordance with U.S. GAAP. Non-GAAP financial measures disclosed by the Company are provided as additional information to analysts, investors and other stakeholders in order to provide them with greater transparency about, or an alternative method for assessing the Company’s financial condition or operating results. These measures are not in accordance with, or a substitute for U.S. GAAP, and may be different from or inconsistent with non-GAAP financial measures used by other companies. Whenever the Company refers to a non-GAAP financial measure, it will also define it or present the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP, along with a reconciliation of the differences between the non-GAAP financial measure it references and such comparable U.S. GAAP financial measure.
(12) Gain recognized on the sale of Stifel Independent Advisors, LLC during the first quarter of 2026.
(13) Primarily related to prejudgment interest recognized on legal matters.
(14) Primarily related to charges attributable to integration-related activities, signing bonuses, amortization of restricted stock awards, debentures, and promissory notes issued as retention, additional earn-out expense, and amortization of intangible assets acquired. These costs were directly related to acquisitions of certain businesses and are not representative of the costs of running the Company’s on-going business.
(15) The Company recorded severance costs associated with workforce reductions in certain of its foreign subsidiaries.
(16) Primarily represents the Company’s effective tax rate for the period applied to the non-GAAP adjustments.
   

Media Contact: Neil Shapiro (212) 271-3447 | Investor Contact: Joel Jeffrey (212) 271- 3610 | www.stifel.com/investor-relations

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) announces that further to its press releases dated September 17, 2026, October 13, 2026, and October 20, 2026 it has extended its non-brokered private placement offering for up to a further thirty (30) days.

The non-brokered private placement offering consists of: (i) common shares of the Company issued on a non-flow-through basis (the “HD Shares”); and (ii) common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) (the “FT Shares” and, together with the HD Shares, the “Shares”), each at a price of $0.05 per Share, for aggregate gross proceeds of a minimum of $2,000,000 and a maximum of $7,000,000, representing the issuance of between 40,000,000 and 140,000,000 Shares (the “Offering”).

The Company closed on the first tranche with subscriptions by Matachewan Consolidated Mines, Limited (TSX.V: MCM-A) (“Matachewan”) and McChip Resources Inc. (TSX.V: MCS) (“McChip” and, together with Matachewan, the “Lead Investors”) for $2,133,790.45 of FT Shares, representing 42,675,809 FT Shares. See the Company’s press release from October 20, 2026 for additional details in relation to the Closing of the first tranche.

The Offering will remain open until the earlier of the sale of the remaining HD Shares and FT Shares and November 6, 2026.

The Offering

The Offering consists of the Shares, each at a price of $0.05 per Share, for aggregate gross proceeds of a maximum of $7,000,000, representing the issuance of up to 140,000,000 Shares.

The Offering will close a second tranche on or about October 23, 2026, with a final closing on or before November 6, 2026. The participants in, and the number of HD Shares and FT Shares to be issued under any further tranches will be determined by the Company and the Lead Investors, provided that the aggregate gross proceeds of the Offering will not exceed $7,000,000. Prior to the final closing of the Offering, the Lead Investors intend to subscribe for HD Shares such that, together with the FT Shares acquired in the first tranche, the Lead Investors will collectively hold up to 19.99% of the issued and outstanding common shares of the Company following completion of the Offering.

The gross proceeds from the sale of the FT Shares will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures”, as those terms are defined in the Tax Act (the “Qualifying Expenditures”), on the Company’s mineral properties in Canada. The Company will renounce the Qualifying Expenditures in favour of the subscribers of the FT Shares with an effective date no later than the date permitted under the Tax Act, in an aggregate amount not less than the gross proceeds raised from the issuance of the FT Shares. The net proceeds from the sale of the HD Shares will be used for exploration and development activities, working capital and general corporate purposes.

All securities issued under the Offering will be subject to a hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws and the policies of the TSX Venture Exchange (the “TSXV”). The Offering remains subject to final acceptance of the TSXV. The Company does not intend to pay finder’s fees in connection with the Offering.

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable securities laws of any state of the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction.

Four insiders of the Company intend to subscribe for 8,700,000 FT Shares and 3,000,000 HD Shares for an aggregate of $585,000 on the closing of the second tranche. The insider private placements are exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (“MI 61-101”) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company which will be issued to the insiders will not exceed 25% of its market capitalization.

About Labrador Gold

Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.

The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects.

The Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.

The Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.

The Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.

The Company has 213,485,788 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.

For more information, please contact:

Roger Moss, President and CEO

Tel: 416-704-8291

Website: www.labradorgold.com

X: @LabGoldCorp

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding the completion, size, pricing, structure and timing of the Offering, including the closing of any further tranches; the number and composition of Shares to be issued under the Offering; the participation of the Lead Investors, insiders and other subscribers; the anticipated use of the proceeds of the Offering; the Company’s intention to incur and renounce Qualifying Expenditures; and the receipt of corporate and TSXV approvals.

Forward-looking statements are based on management’s current expectations, estimates, assumptions and beliefs as of the date of this release, including assumptions regarding the satisfaction of the conditions to closing; the availability of applicable prospectus exemptions; the receipt of all required corporate and regulatory approvals, including the acceptance of the TSXV; the availability of sufficient subscriber demand; the ability of subscribers to fund their subscriptions; the absence of a material adverse change before closing; the availability of Qualifying Expenditures; and the Company’s ability to incur and renounce the Qualifying Expenditures within the periods required under the Tax Act.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Offering may be delayed, reduced, restructured or not completed on the terms described or at all; that the Company may raise less than the maximum amount contemplated; that subscribers may withdraw or fail to fund their subscriptions; that required corporate or regulatory approvals, including TSXV acceptance, may not be obtained; that sufficient Qualifying Expenditures may not be available; that the Company may not incur or renounce Qualifying Expenditures within the periods required under the Tax Act; and the risks described in the Company’s continuous disclosure filings with Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update.

To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

Roivant will also host an investor day on Wednesday, December 9, 2026. To attend the event in person or by webcast, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

About Roivant
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, the timing of potential regulatory approvals for our product and product candidates, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com

Media
Stephanie Lee
stephanie.lee@roivant.com

BrewDog Boleyn

ELLON, Scotland and LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) — BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), and West Ham United Football Club today unveiled Boleyn Brew, a first-of-its-kind fan-created beer built with West Ham supporters and brewed for matchday. From flavour and style to storytelling, branding and name, Hammers helped shape every part of the beer. Boleyn Brew makes its debut at London Stadium this Saturday when West Ham United take on Southampton, with limited-edition cans available to buy online from today.

Created by Hammers, for Hammers, Boleyn Brew brings together BrewDog’s brewing expertise with the pride, loyalty and unmistakable character of the Claret and Blue faithful. As West Ham United’s Official Beer Partner, BrewDog invited a diverse group of supporters into the process from the beginning, asking them what a true West Ham beer should taste like, look like and stand for. After fan consultations produced a shortlist of names, supporters voted for Boleyn Brew — a proud nod to the Boleyn Ground and the memories, matchdays and moments that continue to unite generations of supporters.

BrewDog x West Ham

Supporters came back again and again to three ideas: history, heritage and unpretentious character. The result is a 4.5% Oat Lager with tropical fruit and citrus notes on a smooth, bready lager base — easy-drinking, full of character and made for the rituals that surround the game: meeting mates before kick-off, raising a pint on the concourse, watching from home or celebrating with the West Ham family. The can design features the iconic Boleyn Gates, connecting every pour back to the ground where so many supporters’ memories were made.

Stuart Harrison, Chief Sales Officer, BrewDog, said: “At BrewDog, we believe the best beers are built with the people who drink them. Boleyn Brew is exactly that: a beer shaped by West Ham fans from the first tasting conversation to the name on the can. It captures what makes this club special — heritage, passion, loyalty and a brilliant matchday atmosphere — and it is the kind of fan-first partnership we are proud to bring to life. We cannot wait to pour the first pints at London Stadium this weekend.”

Club legend Carlton Cole joined supporters throughout the consultation process, helping lead the conversation, taste the beer and bring the spirit of West Ham into the room. Cole was also the face of Claret & Brew, BrewDog and West Ham United’s first club-branded beer, which launched in November 2025 and sold out within hours.

Club legend Carlton Cole said: “After being part of Claret & Brew last season, I loved seeing the fans take this one even further and make a beer they can truly call their own. Boleyn Brew has the heart, loyalty and character of West Ham all over it. It is made by Hammers, for Hammers, and I cannot wait to raise a pint of our beer at London Stadium this weekend!”

West Ham United supporter Simon Fell, who was involved from the start of the process, said: “West Ham gets under your skin. It is the football, the people, the memories, the laughs, the tough days, the brilliant days and everything that comes with being a Hammer. From the start, it felt like supporters were genuinely part of creating something that belongs to us. Boleyn Brew feels properly West Ham: light, easy drinking, full of character and rooted in our history through the Boleyn Gates on the can. It is a beer for West Ham people, and I am proud to have played a small part in it. Our club, our memories, our beer. COYI!”

Fellow Hammer Elaine Hopkinson added: “A pint on matchday is part of the ritual — meeting family, friends and fellow fans, talking about the team and feeling that build-up before kick-off. To help create a beer made for West Ham fans by West Ham fans with BrewDog made it even more special. Boleyn Brew is a brilliant name: direct, proud and rooted in our heritage. The can design captures those iconic elements of the old ground perfectly.”

David Chaplin, Director of Commercial Strategy, West Ham United, commented: “BrewDog has put our supporters at the heart of this partnership, and Boleyn Brew is a brilliant example of what that can create. The engagement, energy and passion from our fans has been fantastic to see, and the final beer is something the West Ham family can be proud of. We are excited to launch it at London Stadium and continue working with BrewDog on experiences, activations and products that bring supporters closer to the club on matchdays and throughout the season.”

Boleyn Brew is the latest fan-first moment from BrewDog and West Ham United, building on a partnership designed to show up for supporters on and beyond matchday. The partnership launched in summer 2025, when BrewDog gifted full kits to grassroots teams across east London and Essex. Claret & Brew followed that November, alongside supporter benefits including free pints and discounts across BrewDog’s lineup. The partnership also forms part of BrewDog’s growing presence across the U.K.’s biggest sporting and live event venues, with BrewDog serving as exclusive beer partner of London Stadium and recently announcing a five-year partnership with Leicester Tigers.

Supporters can be among the first to try Boleyn Brew at the BrewDog container bar near Bridge 2 and at the BrewDog Deck at London Stadium from Saturday’s match against Southampton.

Limited-edition cans of Boleyn Brew are available now at www.brewdog.com while stock lasts.

About BrewDog  
BrewDog has always had one mission: making people as passionate about great beer as we are. From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007. Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognizable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future will continue to be shaped by the three things that matter most: People, Planet and Beer.

For more information, visit www.brewdog.com or follow @BrewDog on social media.  

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.  

Tilray Brands Contacts:
Media 
news@tilray.com

Investor Relations 
investors@tilray.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/37ac36c6-fcf8-4122-a015-d3ae9cb5b270
https://www.globenewswire.com/NewsRoom/AttachmentNg/7fa17fb0-1734-402d-ba14-62744eac0f88 

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.

The Company expects named-patient access to be an important component of its international commercialization strategy for Ebstrocel™. Where permitted by local law and implemented through statements of work, this pathway may allow physicians to request Ebstrocel™ for individual eligible patients before local marketing approval or broad commercial availability.

The Uniphar framework is designed to provide the Company with scalable international commercial infrastructure, beginning with named-patient supply, and potentially expanding to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured in individual countries. Depending on the services agreed in individual statements of work, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking. By leveraging Uniphar’s established infrastructure rather than building country-by-country capabilities internally, the Company believes this model provides a capital-efficient path to establish Ebstrocel™’s international commercial footprint and scale as additional markets become available.

“This agreement marks an important step in moving Ebstrocel™ from clinical development toward commercialization and bringing Ebstrocel to patients internationally,” said David Moss, Chief Executive Officer of INmune Bio. “Uniphar provides access to established market-access, distribution and order-to-cash capabilities across multiple international markets without requiring INmune Bio to build those capabilities country by country. We believe this provides a capital-efficient way to pursue named-patient opportunities in appropriate markets while building the physician relationships, treatment-center experience and commercial infrastructure needed to support broader international commercialization.”

 “We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”

About Ebstrocel™

Ebstrocel™ (pobistrocel) is INmune Bio’s investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through the Company’s CORDStrom™ platform for the treatment of RDEB. The platform is designed to address donor variability and manufacturing inconsistency. Ebstrocel™ is investigational and has not been approved by the FDA, MHRA, EMA or any other regulatory authority.

About Uniphar Plc.

Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide. With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.

Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.

Operating across 160 countries with a global team of 3,600+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.

From molecule to market and beyond.

For more information, please visit www.uniphar.com 

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

  • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning toward regulatory and commercial readiness, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. regulatory pathway and development of international access and distribution infrastructure.
     
  • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to reduce pathological neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates are investigational, and there can be no assurance that any clinical, regulatory or commercial objective will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, timing of key milestones, future plans or expectations, the scope and implementation of the Uniphar relationship, the execution of statements of work, the availability and timing of named-patient or expanded-access sales, potential revenue, potential expansion across Europe, the Middle East and North Africa (MENA) or into Latin America, the anticipated capital efficiency of the distribution model, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™ (EbstrocelTM, pobistrocel), XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts: 
David Moss 
Chief Executive Officer 
(561) 710-0512 
info@inmunebio.com

Daniel Carlson 
Head of Investor Relations 
(415) 509-4590 
dcarlson@inmunebio.com

Uniphar Contacts:
Media Contacts:
Uniphar: Heather.Hopkin@teamtala.com and Beth.Oshea@teamtala.com

Enquiries:
Uniphar: NPS_Ebstrocel@uniphar.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.